Competition Law and Cognitive Enhancement Market Competition

Introduction

The cognitive enhancement market covers products and services intended to improve memory, attention, alertness, learning, mental performance, or other cognitive functions. It can include prescription medicines, over-the-counter nootropics, supplements, functional foods and beverages, neurotechnology, brain-computer interfaces, digital cognitive-training platforms, personalized AI-based enhancement services, and related diagnostic/data services.

Competition law becomes particularly important where the market combines health-related products, intellectual property, data, network effects, professional gatekeeping, regulatory approvals, and platform ecosystems.

There is no single competition-law category called a “cognitive enhancement market.” The legal analysis therefore depends on how the relevant market is defined and on the particular conduct involved.

1. Relevant Market Definition

The first issue is identifying the relevant product and geographic market.

Possible product markets may include:

• prescription cognitive-enhancement medicines;
• generic versus branded medicines;
• ADHD-related medicines where enhancement and therapeutic uses overlap;
• nootropic supplements;
• caffeine/energy products;
• digital cognitive-training services;
• neurotechnology and wearable devices;
• brain-computer-interface services;
• cognitive-performance monitoring;
• AI-powered cognitive enhancement platforms;
• integrated hardware/software ecosystems.

A competition authority would examine substitutability, price, functionality, consumer preferences, regulatory constraints and switching costs.

For example, prescription stimulants may not necessarily be in the same relevant market as nutritional supplements simply because both are marketed as improving concentration. Regulatory status, medical supervision, efficacy, safety and consumer use may make them poor substitutes.

Conversely, different technologies may become competitive if consumers use them for substantially similar cognitive-performance purposes.

2. Market Power and Dominance

A company could obtain market power through:

1. proprietary technology;
2. patents;
3. regulatory approvals;
4. exclusive distribution agreements;
5. control of clinical or performance data;
6. large user datasets;
7. strong consumer brands;
8. app-store or platform access;
9. interoperability restrictions;
10. network effects.

The possession of a patent or proprietary technology does not itself establish unlawful dominance. Competition law generally becomes relevant when market power is used in a manner capable of excluding competitors or exploiting customers.

3. Patent and IP-Related Competition Issues

Cognitive-enhancement pharmaceuticals and neurotechnology can be highly dependent on intellectual property.

Potential concerns include:

• patent settlements delaying generic entry;
• patent thickets;
• strategic continuation patents;
• exclusionary licensing;
• discriminatory licensing;
• refusal to license essential technology;
• patent pooling;
• technology tying;
• excessive royalty structures.

The central competition question is whether legitimate protection of innovation is being used as a mechanism to unreasonably prevent competitive entry.

4. Generic Entry and Reverse-Payment Settlements

This is particularly important for pharmaceutical cognitive-enhancement products.

A branded pharmaceutical company may settle patent litigation with a prospective generic entrant. If the settlement involves a substantial payment or other valuable consideration in exchange for delaying market entry, competition authorities may investigate whether the arrangement suppresses potential generic competition.

Case 1: FTC v. Actavis, Inc., 570 U.S. 136 (2013)

The U.S. Supreme Court held that certain reverse-payment patent settlements can be subject to antitrust scrutiny rather than automatically receiving immunity merely because they fall within the patent's exclusionary scope.

Relevance

For cognitive-enhancement medicines, a similar arrangement could arise where:

Brand manufacturer → patent litigation → generic challenger → settlement → delayed generic entry

Competition law may examine:

• size of the payment;
• unexplained commercial justification;
• strength of the patent;
• expected entry date;
• effect on consumers;
• alternative explanations for the settlement.

Thus, patent rights and competition law operate simultaneously rather than existing in completely separate spheres.

5. Exclusive Dealing and Loyalty Rebates

A dominant cognitive-enhancement manufacturer could provide:

• exclusive-distribution discounts;
• loyalty rebates;
• volume rebates;
• preferred-pharmacy incentives;
• exclusive hospital contracts;
• exclusive platform placement.

These arrangements can produce efficiencies, but they can also make it difficult for smaller competitors to obtain distribution.

Case 2: Intel Corp. v. Commission, Case C-240/22 P

EU competition jurisprudence concerning Intel's loyalty rebates illustrates the importance of examining whether rebate schemes employed by dominant undertakings have the capability of foreclosing competitors and, where relevant, considering an as-efficient-competitor analysis. The 2024 judgment addressed evidentiary and economic-analysis issues surrounding loyalty rebates under Article 102 TFEU.

Application

Suppose a dominant cognitive-enhancement company tells pharmacies:

“Receive substantially better rebates if 90% of your cognitive-performance products are purchased from us.”

The legal assessment would examine whether the arrangement:

• forecloses competing products;
• covers a substantial portion of demand;
• makes switching commercially difficult;
• has legitimate efficiency explanations;
• harms competition rather than merely individual competitors.

6. Information and Data Restrictions

Cognitive-enhancement markets may depend heavily on data.

Examples include:

• cognitive-performance datasets;
• clinical trial information;
• wearable-device data;
• EEG datasets;
• user behavioural data;
• effectiveness data;
• pharmacovigilance information;
• AI-training datasets.

A dominant platform might restrict access to information necessary for competitors to provide competing services.

Case 3: FTC v. Indiana Federation of Dentists, 476 U.S. 447 (1986)

The U.S. Supreme Court considered a collective refusal by dentists to provide insurers with requested X-rays. The Court applied the rule of reason and accepted that concerted conduct restricting access to information could suppress competition.

Relevance

The case provides a useful analytical analogy for cognitive-enhancement ecosystems.

For example, competing cognitive-health platforms might need access to certain performance information to provide independent assessments. A collective agreement among providers to withhold such information could raise competition concerns if it substantially reduces competitive choice.

7. Tying and Bundling

Cognitive-enhancement businesses may operate across multiple complementary markets.

Examples:

Neuro-device + software

Cognitive assessment + enhancement subscription

AI assistant + proprietary cognitive-training service

Wearable + cloud analytics

Prescription product + digital monitoring platform

A dominant undertaking could potentially make one product conditional on purchasing another.

Competition authorities may distinguish legitimate product integration from exclusionary tying.

Case 4: United States v. Microsoft Corp., 253 F.3d 34 (D.C. Cir. 2001)

The Microsoft litigation examined exclusionary conduct involving the integration of Internet Explorer with Windows and Microsoft's conduct toward competing browser technologies.

Relevance

The principles are potentially relevant where a dominant cognitive-technology ecosystem uses control over one product to disadvantage a competing complementary product.

For example:

dominant neurotechnology hardware → compulsory proprietary cognitive-analysis software → exclusion of independent software providers.

The legal question would be whether the integration produces legitimate consumer benefits or instead unlawfully forecloses competition.

8. Self-Preferencing by Cognitive Platforms

A platform could simultaneously operate:

• a cognitive-enhancement marketplace;
• a cognitive-training service;
• a neurotechnology platform;
• an AI enhancement application.

This creates a potential vertical conflict of interest.

The platform could rank its own product above competing products.

Potential conduct includes:

• preferential search ranking;
• preferential recommendation;
• reduced visibility for rivals;
• preferential access to user data;
• discriminatory API access;
• preferential technical integration.

The competition analysis would consider market power, foreclosure, consumer harm and legitimate platform efficiencies.

9. Pharmaceutical Distribution and Vertical Restraints

Cognitive-enhancement pharmaceutical products can move through:

manufacturer → wholesaler → pharmacy → healthcare professional → consumer

Competition concerns may arise from:

• territorial restrictions;
• resale-price restrictions;
• exclusive distribution;
• customer allocation;
• discriminatory supply;
• loyalty rebates;
• restrictions on online sales.

Case 5: Leegin Creative Leather Products, Inc. v. PSKS, Inc., 551 U.S. 877 (2007)

The U.S. Supreme Court held that resale-price-maintenance agreements are evaluated under the rule of reason rather than automatically treated as per se unlawful under federal antitrust law.

Application

If a cognitive-enhancement manufacturer imposes minimum resale prices on pharmacies or online sellers, the legal analysis would examine:

• market structure;
• market power;
• potential free-riding justifications;
• effects on price competition;
• effects on competing distributors.

The treatment can differ substantially across jurisdictions.

10. Collective Action and Professional Associations

Cognitive-enhancement markets may involve physicians, pharmacists, neuroscientists, clinics and professional associations.

Professional rules can sometimes legitimately protect:

• patient safety;
• scientific integrity;
• professional ethics;
• quality standards.

But collective rules can become competition problems where they unnecessarily restrict market competition.

Case 6: National Society of Professional Engineers v. United States, 435 U.S. 679 (1978)

The U.S. Supreme Court rejected a professional association's ethical rule prohibiting competitive bidding, emphasizing that professional or ethical motivations do not automatically remove commercial restraints from antitrust scrutiny.

Relevance

Suppose an association of cognitive-enhancement clinics collectively prohibits members from:

• advertising prices;
• offering competing service packages;
• using particular technologies;
• collaborating with competing platforms.

The fact that the restriction is described as an “ethical standard” would not by itself resolve the competition-law question.

11. Cartels and Coordinated Pricing

The market could also experience traditional cartel conduct.

Possible examples include competing manufacturers agreeing to:

• fix prices;
• divide customers;
• allocate territories;
• restrict production;
• coordinate discounts;
• exchange competitively sensitive information.

These are substantially more serious competition-law risks than ordinary unilateral commercial conduct.

Recent pharmaceutical illustration

In September 2026, Poland's competition authority announced a major pharmaceutical-wholesaler cartel case involving alleged coordination supported by exchange of pricing information obtained through pharmacy loyalty programs. The authority stated that the three largest affected groups controlled more than 70% of the wholesale market; the decision remains subject to appeal.

Application

A similar information-exchange arrangement among cognitive-enhancement manufacturers could facilitate coordinated pricing even without an explicit written agreement fixing prices.

12. Data as a Competitive Asset

Data may become a particularly important source of competitive advantage.

A cognitive-enhancement platform may accumulate:

• millions of user interactions;
• cognitive-performance measurements;
• response-to-intervention data;
• longitudinal behavioural information;
• neurophysiological data;
• personalized treatment information.

A large dataset may create economies of scale and learning effects.

Competition authorities could therefore examine whether a dominant undertaking:

• prevents portability;
• restricts interoperability;
• prevents competitors from accessing necessary data;
• combines datasets from adjacent markets;
• uses data obtained from one market to exclude competitors in another.

However, competition law does not automatically create a general right to obtain another company's commercially valuable data.

13. AI and Algorithmic Cognitive Enhancement

AI can create another layer of competition concerns.

A dominant AI-powered cognitive-enhancement platform could use algorithms for:

• personalised recommendations;
• pricing;
• product ranking;
• user segmentation;
• treatment recommendations;
• advertising;
• performance optimization.

Potential risks include:

1. algorithmic discrimination;
2. exclusionary ranking;
3. personalized foreclosure;
4. algorithmic coordination;
5. discriminatory access to APIs;
6. leveraging data advantages;
7. tying AI services to proprietary hardware.

The competition analysis should distinguish independent algorithmic decision-making from unlawful coordination or exclusionary conduct.

14. Network Effects and Ecosystem Lock-In

Cognitive-enhancement platforms may have strong network effects.

For example:

More users → more performance data → better algorithm → better service → more users

This can produce a feedback loop.

Additional lock-in may arise from:

• proprietary data formats;
• incompatible devices;
• non-portable user profiles;
• subscription history;
• personalized AI models;
• proprietary accessories;
• switching costs.

Competition authorities may therefore examine multi-homing and switching costs.

If consumers can easily use multiple cognitive-enhancement platforms simultaneously, network effects may be less exclusionary.

15. Essential Facilities and Interoperability

A particularly important issue arises where a dominant firm controls infrastructure that competitors need.

Potential examples include:

• dominant neurotechnology interfaces;
• proprietary cognitive-data repositories;
• dominant app marketplaces;
• essential interoperability protocols;
• specialized processing infrastructure.

A refusal to provide access is not automatically unlawful.

The assessment may consider:

• indispensability;
• feasibility of duplication;
• actual or potential competition;
• objective justification;
• discriminatory treatment;
• effect on downstream competition.

16. Merger Control

Mergers could significantly reshape cognitive-enhancement markets.

Examples:

Horizontal merger

Two competing nootropic manufacturers merge.

Vertical merger

A neuro-device manufacturer acquires a cognitive-training platform.

Conglomerate merger

A major AI company acquires:

• neurotechnology;
• cognitive-performance datasets;
• digital health platforms;
• wearable technology.

Data-driven acquisition

A large technology company acquires a smaller cognitive platform principally to obtain its proprietary dataset.

Competition authorities may investigate:

• horizontal overlaps;
• vertical foreclosure;
• access to data;
• innovation competition;
• potential competitors;
• ecosystem effects;
• elimination of future competition.

17. Innovation Competition

Traditional competition analysis often examines price, output and consumer choice.

Cognitive enhancement requires particular attention to innovation competition because companies may compete through:

• improved efficacy;
• reduced side effects;
• improved personalization;
• new delivery mechanisms;
• better neurotechnology;
• improved AI models;
• better interoperability.

A merger that leaves current prices unchanged could nevertheless reduce future innovation competition.

This is particularly significant where emerging technology firms are potential competitors rather than major current competitors.

18. Consumer Welfare and Quality

Competition harm in this market is not necessarily limited to higher prices.

Potential dimensions include:

• reduced quality;
• reduced efficacy;
• reduced safety;
• less privacy;
• reduced interoperability;
• less innovation;
• fewer choices;
• higher switching costs;
• deterioration in service.

For example, a “free” cognitive-enhancement platform could still generate competitive concerns if its dominance allows it to reduce privacy protections or quality while eliminating competing alternatives.

19. Six Key Case Laws — Quick Revision Table

20. Competition-Law Risk Matrix

21. India-Specific Framework

For an Indian competition-law analysis, the principal statute is the Competition Act, 2002, administered by the Competition Commission of India.

Relevant provisions include:

Section 3

Prohibits agreements having or likely to have an appreciable adverse effect on competition.

Relevant cognitive-enhancement examples:

• price fixing;
• market allocation;
• bid coordination;
• information exchange;
• restrictive vertical arrangements.

Section 4

Addresses abuse of dominant position.

Potential applications include:

• discriminatory access to cognitive-enhancement platforms;
• unfair conditions;
• refusal of access;
• leveraging;
• exclusionary rebates;
• tying/bundling.

Sections 5–6

Concern combinations and merger control.

These become relevant to acquisitions involving:

• pharmaceutical companies;
• neurotechnology companies;
• AI platforms;
• cognitive-data businesses;
• digital health ecosystems.

22. Overall Legal Framework

The competition analysis can be represented as:

Cognitive Enhancement Product/Platform

↓

Define Relevant Market

↓

Assess Market Power

↓

Identify Conduct

↓

Horizontal / Vertical / Unilateral / Merger Conduct

↓

Assess Foreclosure or Competitive Harm

↓

Consider Pro-Competitive Justifications

↓

Examine Consumer and Innovation Effects

↓

Competition-Law Remedy

Possible remedies include:

• cease-and-desist orders;
• behavioural commitments;
• access obligations;
• interoperability requirements;
• modification of agreements;
• non-discrimination requirements;
• divestiture in merger cases;
• monetary penalties where authorised.

Conclusion

The cognitive enhancement market presents a particularly complex competition-law environment because pharmaceutical products, supplements, neurotechnology, AI, digital platforms and cognitive-performance data may converge into integrated ecosystems.

The principal competition questions are likely to concern market definition, patent-related exclusion, generic entry, exclusive distribution, loyalty rebates, tying, data access, interoperability, platform self-preferencing, professional restrictions, algorithmic coordination and technology-driven mergers.

The six leading authorities above demonstrate that conventional competition-law doctrines—reverse-payment scrutiny, information restraints, loyalty rebates, tying, resale-price restraints and professional self-regulation—can provide useful analytical foundations even where the underlying cognitive-enhancement technology is new.